Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
26°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
India Globalization Capital Inc
(NY:
IGC
)
0.4789
+0.0028 (+0.59%)
Streaming Delayed Price
Updated: 9:45 AM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about India Globalization Capital Inc
< Previous
1
2
3
Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
April 16, 2024
Via
Benzinga
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
April 16, 2024
IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo.
Via
Benzinga
Who's Who In Cannabis: Latest Executive Changes You Should Know About
April 15, 2024
Via
Benzinga
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research
April 03, 2024
--News Direct--
Via
News Direct
IGC Raises $3M Via Private Placement With Asset Management Firm Bradbury
July 06, 2023
IGC Pharma, Inc. (AMEX: IGC) bagged a strategic investment
Via
Benzinga
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research
April 02, 2024
Via
Benzinga
EXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early Success
March 20, 2024
IGC Pharma's breakthrough Alzheimer's drug, IGC-AD1, shows promising interim results in reducing cognitive and behavioral symptoms, offering hope for patients and families. Its dual-action capability...
Via
Benzinga
Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
March 20, 2024
IGC Pharma unveils interim results of Phase 2 trial of IGC-AD1 for Agitation in Alzheimer's Dementia. Shows reduction in agitation vs. placebo observed.
Via
Benzinga
Benzinga's 2024 Virtual Healthcare: What's Next In Health?
March 19, 2024
The 2024 Benzinga Virtual Healthcare Summit brings together top healthcare professionals and companies to discuss industry trends, advancements in technology, and the future of healthcare. Don't miss...
Via
Benzinga
IGC Pharma Advances In Alzheimer's Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1
March 19, 2024
--News Direct--
Via
News Direct
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 28, 2024
Via
Benzinga
IGC Pharma Announces Q3 2024 Earnings: Strategic Patent Achievements Propel Forward Amid Losses
February 19, 2024
IGC Pharma's Q3 2024 results: Navigating financial dips with strategic patents in pain treatment and Alzheimer's therapy.
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Why IGC Pharma Stock Is Moving Higher
January 23, 2024
IGC Pharma highlighted data from a trial in which the group treated with TGR-63 showed a 78% and 85% reduction in the cortical and hippocampal amyloid load, respectively, reaffirming its potential to...
Via
Benzinga
AI And THC: IGC Pharma Teams Up With Colombian University For Alzheimer's Treatment Research
November 21, 2023
IGC Pharma partners with University of Los Andes, to leverage AI for improving Alzheimer's disease treatment and clinical trial efficiency.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Cannabis Based Pain Relief Solution Receives European Patent Approval
October 20, 2023
IGC Pharma, Inc. (NYSE American: IGC) has been granted European Patent No. 3193862 by the European Patent Office for its innovative "Cannabinoid Composition and Method for Treating Pain."
Via
Benzinga
Topics
Cannabis
Intellectual Property
Exposures
Cannabis
Intellectual Property
12 Health Care Stocks Moving In Thursday's After-Market Session
September 21, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
September 12, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
September 01, 2023
Via
Benzinga
IGC Pharma FY23 Revenue Grows 129%, What About Net Loss?
July 12, 2023
IGC Pharma, Inc. (AMEX:IGC) released its financial results for the fiscal year ended March 31, 2023, revealing revenue of $911,000, an increase of 129% compared to $397,000 in fiscal year 2022. FY 2023...
Via
Benzinga
IGC Pharma Secures $12M Credit Facility From O-Bank To Aid Alzheimer's Research
July 07, 2023
IGC Pharma, Inc. (AMEX: IGC) has recently secured a $12 million credit from the
Via
Benzinga
IGC Pharma Secures $3M Via Private Placement
July 06, 2023
IGC Pharma, Inc. (AMEX:IGC) announced a strategic investment from four investment funds managed by Bradbury Asset Management (Hong Kong) Limited, an asset management firm with over $2 billion in...
Via
Benzinga
Why VBI Vaccines Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket
July 06, 2023
Gainers Akumin Inc. (NASDAQ: AKU) shares surged 58.2% to $0.2865 in pre-market trading. Akumin recently named Krishna Kumar as President and Chief Operating Officer of the Company.
Via
Benzinga
12 Industrials Stocks Moving In Tuesday's Pre-Market Session
June 27, 2023
Via
Benzinga
IGC Announces Rebranding, Changes Name To IGC Pharma
March 20, 2023
India Globalization Capital, Inc. (AMEX:IGC) announced it will begin operating under the new name IGC Pharma, Inc., (dba IGC) effective March 30, 2023, as part of a rebranding strategy that better...
Via
Benzinga
IGC Q3 2023 Revenue Grows 133% YoY, What About Net Loss?
February 15, 2023
India Globalization Capital, Inc. (dba IGC, Inc.) (AMEX:IGC) released its third fiscal quarter 2023 financial results, revealing revenue of $332,000, a 133% increase compared to $142,000 in the Q3...
Via
Benzinga
IGC Expanding Clinical Trials Of THC Based Drug Following Approval From Health Canada
January 04, 2023
India Globalization Capital, Inc. (AMEX:IGC) has received a no objection letter from Health Canada for approval of its trial, “A phase 2, multi-center, double-blind, randomized, placebo-controlled...
Via
Benzinga
IGC Starts Phase 2 Clinical Trials Of THC Based Drug Candidate For The Treatment Of Agitation In Dementia From Alzheimer's Disease
December 01, 2022
India Globalization Capital, Inc. (AMEX:IGC) has begun “A phase 2, multi-center, double-blind, randomized, placebo-controlled, trial of the safety and efficacy of IGC-AD1 on agitation in participants...
Via
Benzinga
IGC Q2 2023 Revenue Grows 261%, THC Based Drug For Alzheimer's Entering Phase 2 Trials
November 02, 2022
India Globalization Capital, Inc. (AMEX:IGC) reported its second fiscal quarter 2023 financial results, revealing revenue of $202,000, a 261% increase compared to $56,000 in the same quarter of 2022.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
September 28, 2022
It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning.
Via
InvestorPlace
IGC Announces Issuance Of Second Patent For The Treatment Of Alzheimer's Using THC
September 21, 2022
India Globalization Capital, Inc. (AMEX:IGC) announced that the United States Patent and Trademark Office issued a second patent (#11,446,276) for the treatment of Alzheimer’s disease entitled “Extreme...
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.